PE20191146A1 - Inhibidores de magl - Google Patents
Inhibidores de maglInfo
- Publication number
- PE20191146A1 PE20191146A1 PE2019001015A PE2019001015A PE20191146A1 PE 20191146 A1 PE20191146 A1 PE 20191146A1 PE 2019001015 A PE2019001015 A PE 2019001015A PE 2019001015 A PE2019001015 A PE 2019001015A PE 20191146 A1 PE20191146 A1 PE 20191146A1
- Authority
- PE
- Peru
- Prior art keywords
- hexafluoropropan
- piperazin
- oxy
- carbonyl
- phenyl
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title 1
- 101710116393 Monoglyceride lipase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 (4 - (((1,1,1,3,3,3-hexafluoropropan-2-yl) oxy) carbonyl) piperazin-1-yl) methyl Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 abstract 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423095P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191146A1 true PE20191146A1 (es) | 2019-09-02 |
Family
ID=62107273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001015A PE20191146A1 (es) | 2016-11-16 | 2017-11-15 | Inhibidores de magl |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9981930B1 (enExample) |
| EP (1) | EP3541822B1 (enExample) |
| JP (1) | JP6987859B2 (enExample) |
| KR (1) | KR20190077087A (enExample) |
| CN (1) | CN110248947B (enExample) |
| AR (1) | AR110088A1 (enExample) |
| AU (1) | AU2017361250A1 (enExample) |
| BR (1) | BR112019009991A2 (enExample) |
| CA (1) | CA3043612A1 (enExample) |
| CL (1) | CL2019001335A1 (enExample) |
| CO (1) | CO2019005038A2 (enExample) |
| CR (1) | CR20190243A (enExample) |
| DO (1) | DOP2019000121A (enExample) |
| EA (1) | EA201991074A1 (enExample) |
| EC (1) | ECSP19035377A (enExample) |
| ES (1) | ES2908632T3 (enExample) |
| IL (1) | IL266550A (enExample) |
| JO (1) | JOP20190105A1 (enExample) |
| MA (1) | MA46860A (enExample) |
| MX (1) | MX2019005771A (enExample) |
| NI (1) | NI201900050A (enExample) |
| PE (1) | PE20191146A1 (enExample) |
| PH (1) | PH12019501102A1 (enExample) |
| RU (1) | RU2019116514A (enExample) |
| TN (1) | TN2019000150A1 (enExample) |
| TW (1) | TW201831458A (enExample) |
| WO (1) | WO2018093946A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2800565T1 (sl) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Karbamatne spojine in metode izdelave in uporabe le-teh |
| JP2018515460A (ja) | 2015-05-11 | 2018-06-14 | アビデ セラピューティクス，インク． | 炎症または神経障害性疼痛を処置する方法 |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2017361254B2 (en) | 2016-11-16 | 2021-09-23 | H. Lundbeck A/S. | Pharmaceutical formulations |
| KR102508739B1 (ko) | 2016-11-16 | 2023-03-09 | 하. 룬드벡 아크티에셀스카브 | Magl 억제제의 결정형 |
| PE20200664A1 (es) | 2017-08-29 | 2020-06-11 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso |
| CN111448199A (zh) * | 2017-11-02 | 2020-07-24 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺 |
| TW201946906A (zh) | 2018-05-15 | 2019-12-16 | 美商阿拜德生物製藥公司 | Magl抑制劑 |
| US11702393B2 (en) * | 2020-04-21 | 2023-07-18 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| JP7777891B2 (ja) | 2021-12-29 | 2025-12-01 | サイ セラピューティクス インコーポレイテッド | モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害 |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1593586A (enExample) | 1967-10-17 | 1970-06-01 | ||
| JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
| WO1989011794A1 (fr) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Inhibiteur de la croissance de plantes |
| DE69211015T2 (de) | 1991-11-27 | 1997-01-09 | Du Pont | Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate |
| AU1384795A (en) | 1993-12-22 | 1995-07-10 | Shell Internationale Research Maatschappij B.V. | Process for preparing carbamates |
| AU7579696A (en) | 1995-11-15 | 1997-06-05 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
| WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
| JP2003511362A (ja) | 1999-10-04 | 2003-03-25 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー | 新規カルバメートおよび尿素類 |
| EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
| KR20070026382A (ko) | 2004-02-18 | 2007-03-08 | 아스트라제네카 아베 | 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도 |
| WO2005100321A1 (en) * | 2004-04-07 | 2005-10-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| CN101087786A (zh) | 2004-12-23 | 2007-12-12 | 霍夫曼-拉罗奇有限公司 | 杂环氨基甲酸酯衍生物，它们的制备及作为药剂的应用 |
| DK2937341T3 (en) | 2004-12-30 | 2017-09-11 | Janssen Pharmaceutica Nv | 4- (BENZYL) -PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID HYDROLASE (FAAH) FOR TREATING ANALYSIS, PAIN AND OTHER CONDITIONS |
| JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎の治療方法 |
| JP2009527459A (ja) | 2006-02-23 | 2009-07-30 | 武田薬品工業株式会社 | 縮合窒素含有複素環化合物 |
| CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| US20110118286A1 (en) | 2008-07-16 | 2011-05-19 | Santhosh Francis Neelamkavil | Bicyclic heterocycle derivatives and their use as gpcr modulators |
| US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| EP2411010B1 (en) | 2009-03-23 | 2013-11-06 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| RU2570662C9 (ru) | 2009-11-03 | 2016-07-20 | Байер Матириальсайенс Аг | Фторуретаны в качестве добавки в фотополимерной композиции |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| SI2800565T1 (sl) | 2012-01-06 | 2020-10-30 | Lundbeck La Jolla Research Center, Inc. | Karbamatne spojine in metode izdelave in uporabe le-teh |
| CN108912066B (zh) | 2012-01-06 | 2022-06-24 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| MX2014011134A (es) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| JP6647592B2 (ja) * | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| EP3271352B1 (en) | 2015-03-18 | 2021-05-12 | H. Lundbeck A/S | Piperazine carbamates and methods of making and using same |
| JP2018515460A (ja) * | 2015-05-11 | 2018-06-14 | アビデ セラピューティクス，インク． | 炎症または神経障害性疼痛を処置する方法 |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| EP3455226B1 (en) * | 2016-05-12 | 2020-12-30 | Lundbeck La Jolla Research Center, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
-
2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/ar unknown
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-15 ES ES17871883T patent/ES2908632T3/es active Active
- 2017-11-15 CR CR20190243A patent/CR20190243A/es unknown
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/es unknown
- 2017-11-15 MA MA046860A patent/MA46860A/fr unknown
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/en active Active
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/ko not_active Withdrawn
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/zh not_active Expired - Fee Related
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/ru not_active Application Discontinuation
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/ja not_active Expired - Fee Related
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/en not_active Ceased
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 EA EA201991074A patent/EA201991074A1/ru unknown
- 2017-11-15 CA CA3043612A patent/CA3043612A1/en not_active Abandoned
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/es unknown
- 2017-11-15 AR ARP170103183A patent/AR110088A1/es unknown
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/pt not_active Application Discontinuation
- 2017-11-15 US US15/814,318 patent/US9981930B1/en active Active
- 2017-11-16 TW TW106139750A patent/TW201831458A/zh unknown
-
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/es unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/es unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/es unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/es unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20190243A (es) | 2019-06-26 |
| ES2908632T3 (es) | 2022-05-03 |
| CO2019005038A2 (es) | 2019-05-31 |
| TN2019000150A1 (en) | 2020-10-05 |
| RU2019116514A (ru) | 2020-12-17 |
| EP3541822A1 (en) | 2019-09-25 |
| US9981930B1 (en) | 2018-05-29 |
| IL266550A (en) | 2019-07-31 |
| AR110088A1 (es) | 2019-02-20 |
| MX2019005771A (es) | 2019-12-05 |
| ECSP19035377A (es) | 2019-05-31 |
| NI201900050A (es) | 2019-10-30 |
| BR112019009991A2 (pt) | 2019-08-27 |
| JP2020502047A (ja) | 2020-01-23 |
| CN110248947A (zh) | 2019-09-17 |
| CA3043612A1 (en) | 2018-05-24 |
| CN110248947B (zh) | 2022-04-01 |
| AU2017361250A1 (en) | 2019-05-30 |
| JP6987859B2 (ja) | 2022-01-05 |
| MA46860A (fr) | 2019-09-25 |
| EP3541822B1 (en) | 2022-01-19 |
| CL2019001335A1 (es) | 2019-10-04 |
| DOP2019000121A (es) | 2019-09-30 |
| WO2018093946A1 (en) | 2018-05-24 |
| KR20190077087A (ko) | 2019-07-02 |
| US20180134675A1 (en) | 2018-05-17 |
| EA201991074A1 (ru) | 2019-12-30 |
| JOP20190105A1 (ar) | 2019-05-09 |
| EP3541822A4 (en) | 2020-04-29 |
| PH12019501102A1 (en) | 2019-08-19 |
| TW201831458A (zh) | 2018-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191146A1 (es) | Inhibidores de magl | |
| PE20211385A1 (es) | Inhibidores de magl | |
| PE20121518A1 (es) | Bloqueantes de los canales de sodio dependientes de voltaje | |
| PE20191144A1 (es) | Inhibidores de magl | |
| JOP20190182A1 (ar) | أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga | |
| HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
| PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| RU2006119510A (ru) | Фенильные производные в качестве ppar агонистов | |
| AR114886A1 (es) | Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2005536475A5 (enExample) | ||
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| HRP20220263T1 (hr) | Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi | |
| PE20170669A1 (es) | Compuesto heterociclico | |
| PE20121280A1 (es) | Derivados de (tio)morfolina como moduladores de s1p | |
| JP2017509694A5 (enExample) | ||
| CL2024000758A1 (es) | Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético | |
| HRP20170539T1 (hr) | Hidroksialifatski supstituirani derivati fenilaminoalkil-etera | |
| CO2021011836A2 (es) | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas | |
| CY1124733T1 (el) | Antimykhtiaσιko φαρμακευτικο σκευασμα | |
| EA202191833A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| EA202191620A1 (ru) | Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения | |
| MX2019007327A (es) | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales. |